Clinical efficacy and safety analysis of human interferon α1b for injection combined with budesonide inhalation in the treatment of infantile pneumonia
Objective:To analyze the clinical efficacy and safety of human interferon α1b for injection combined with budesonide inhalation in the treatment of pediatric pneumonia.Methods:The clinical data of 118 children with pneumonia admitted to our hospital from January 2022 to December 2023 were retrospectively collected.According to the different treatment methods,the children were divided into control group(budesonide inhalation treatment,58 cases)and experimental group(human interferon α1b for injection+budesonide inhalation treatment,60 cases).The clinical efficacy,symptom resolution time,inflammatory factors[Interleukin-6(IL-6),C-reactive protein(CRP)levels]and adverse reactions of the two groups were analyzed and compared.Results:The total therapeutic effect rate of experimental group was significantly higher than that of control group(P<0.05).The time of lung rales disappearance,cough disappearance and body temperature recovery in experimental group were significantly shorter than those in control group(P<0.05).After treatment,the levels of CRP and IL-6 in both groups were significantly decreased,and the levels of CRP and IL-6 in the experimental group were significantly lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion:Human interferon α1b for injection combined with budesonide inhalation in the treatment of infantile pneumonia can improve therapeutic effect,reduce inflammatory response,and have high safety.
Injection of human interferon α1bBudesonidePneumoniaClinical effectSecurity
NETL
NSTL
万方数据
